Cytokinetics | Muscle Biology Therapies

Now Available | Primary Results of GALACTIC-HF Published in NEJM

Read the primary results from GALACTIC-HF, the Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure, published in the New England Journal of Medicine.

cardiovascular disease

Cardiovascular diseases are the leading cause of death in the U.S. and in many places around the world. We’re focused on finding potential treatments for people with heart failure and hypertrophic cardiomyopathy.

NEUROMUSCULAR DISEASE

Neuromuscular diseases can cause loss of muscle function, muscle weakness and fatigue. Our goal is develop potential therapies for people with amyotrophic lateral sclerosis and spinal muscular atrophy.

Press Releases

January 13, 2021Cytokinetics Announces First Patient Dosed in Cohort 2 of REDWOOD-HCM
January 11, 2021Cytokinetics Granted Orphan Drug Designation for CK-3773274 for the Treatment of Hypertrophic Cardiomyopathy
January 6, 2021Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

view all

Cytokinetics Corporate Presentation

Download

Pipeline

We have robust pipeline of small molecule muscle activators and inhibitors, including omecamtiv mecarbil, reldesemtiv, CK-274, CK-136 and CK-601.

Careers

We seek exceptional individuals to join us in our mission to develop the next generation of novel small molecule muscle-directed potential medicines.